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Increased phagocytic nicotinamide adenine dinucleotide phos-
phate oxidase–dependent superoxide production in patients
with early chronic kidney disease.
Background. Oxidative stress has been implicated in the
pathogenesis of atherosclerosis that develops in patients with
advanced chronic kidney disease (CKD). This study was
designed to investigate whether a relationship exists be-
tween phagocytic nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase–dependent superoxide anion (•O2−) pro-
duction and subclinical atherosclerosis in patients with early
CKD.
Methods. Superoxide production was assayed by chemilumi-
nescence under baseline and stimulated conditions on mononu-
clear cells obtained from asymptomatic patients with stage 1
to 2 CKD (N = 22) and healthy controls (N = 21). Ultrasono-
graphic determination of carotid intima-media thickness (IMT)
was used to assess the presence of atherosclerosis.
Results. Although there were no differences in baseline •O2−
production between controls and patients, the •O2− production
in phorbol myristate acetate–stimulated mononuclear cells was
increased (P < 0.05) in patients compared with controls. The
phorbol myristate acetate–induced •O2− production was com-
pletely abolished by apocynin, a specific inhibitor of NADPH
oxidase. A direct correlation (r = 0.441, P < 0.05) was found
between plasma insulin levels and NADPH oxidase–mediated
•O2− production in patients. Carotid IMT was higher (P <
0.005) in patients than in controls. Carotid IMT values above the
upper normal limit in controls were found in 70% and 40% of
patients with increased or normal NADPH oxidase–mediated
•O2− production, respectively.
Conclusion. Generation of •O2− that is mainly dependent on
NADPH oxidase is abnormally enhanced in patients with early
CKD. It is suggested that this alteration could be related to the
development of subclinical atherosclerosis in these patients.
Patients with stage 3 to 5 chronic kidney disease
(CKD), according to the National Kidney Foundation
Key words: chronic kidney disease, mononuclear cells, NADPH
oxidase.
C© 2005 by the International Society of Nephrology
Practice Guidelines for Chronic Kidney Disease [1], ap-
pear to be at greater risk of developing atherosclerosis
and its associated morbidity and mortality [2]. Thus, most
patients with stage 3 to 5 CKD will die of cardiovascular
complications before developing end-stage renal disease
[3]. Oxidative stress has been proposed to play a major
role in the development of atherosclerosis in these pa-
tients [4]. Clinical assessment of oxidative stress in these
patients is based on the finding of increased blood concen-
trations of reactants resulting from oxidation by reactive
oxygen species [5].
A number of findings supports the notion that super-
oxide anion (•O2−) plays an important role in the patho-
physiology of atherosclerosis [6]. For instance, enhanced
generation of •O2− may facilitate oxidative modification
of low-density lipoproteins (LDL), which play a key role
in the formation of atherosclerotic lesions [7]. The nicoti-
namide adenine dinucleotide phosphate (NADPH) oxi-
dase system is considered the most important source of
•O2− in vascular cells [8], and a number of studies have
demonstrated the involvement of this oxidase in experi-
mental and clinical atherosclerosis [9]. NADPH oxidase
is also the major inducible source of •O2− in phagocytic
cells, including lymphocytes, monocytes, and neutrophils
[9]. Interestingly, enhanced phagocytic NADPH oxidase
activity has been recently shown to be associated with
carotid atherosclerosis in asymptomatic patients [10].
A recent review of the literature has demonstrated
that the association between kidney dysfunction and
atherosclerosis-related cardiovascular risk appears early
during the evolution of kidney disease [11]. Thus, we have
hypothesized that phagocytic NADPH oxidase overactiv-
ity may be present in patients with early CKD. To test this
hypothesis, NADPH oxidase–mediated •O2− production
by mononuclear cells was assessed in healthy controls and
patients with stage 1 to 2 CKD according to the National
Kidney Foundation Practice Guidelines for Chronic Kid-
ney Disease [1].
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METHODS
The study population consisted of two groups of pa-
tients who attended for routine medical examination
at the University Clinic of Navarra. The CKD group
consisted of 22 stage 1 to 2 CKD patients with no clin-
ical manifestations of atherosclerotic disease. All pa-
tients exhibited a urine albumin-to-urine creatinine ratio
>17 mg/g (men) or >25 mg/g (women) on two mea-
surements. Glomerular filtration rate (GFR) estimated
from serum creatinine by abbreviated Modification of
Diet in Renal Disease Study equation was ≥90 mL/min/
1.73 m2 in patients with stage 1 CKD and <90 and
≥60 mL/min/1.73 m2 in patients with stage 2 CKD. The
control group consisted of 21 apparently healthy patients
with no pathologic abnormalities or markers of kidney
damage. All patients gave written informed consent to
participate in the study, and the Institutional Review
Committee of the University Clinic approved the proto-
col. The study conformed to the principles of the Helsinki
Declaration.
Blood and urine samples were collected after an
overnight (12-14 hour) fast, and biochemical and hor-
monal parameters were determined by standard labora-
tory protocols. All patients underwent ultrasonography
of the common carotid arteries, and carotid artery intima-
media thickness (IMT) was determined as previously
reported [12].
Phagocytic cells were isolated from blood samples us-
ing a Ficoll-Hypaque gradient. Luminescence assays with
lucigenin (10 lmol/L; Sigma, St. Louis, MO, USA) as the
electron acceptor were used to measure •O2− produc-
tion in 4 × 105 mononuclear cells that were incubated at
37◦C for 30 minutes alone or in the presence of stimuli or
inhibitors, as previously reported [13]. The reaction was
started by the addition of lucigenin to cell samples. Lumi-
nescence was measured every 11 seconds for 5 minutes in
a tube luminometer (Berthold Detection System, Sirius,
Pforzheim, Germany). A buffer blank was subtracted
from each reading. The determinations were performed
under baseline conditions and also after maximum stimu-
lation by the protein kinase C activator, phorbol myristate
acetate (PMA, 2 mg/L, Sigma) at 37◦C. A kinetic study of
baseline and stimulated mononuclear cell response was
carried out, and the value of the area under the curve was
used to quantify chemiluminescence. Data are expressed
as relative light units produced per second (RLU/s). In
some experiments, the effect of diphenylene iodonium
(5 lmol/L; Sigma), a flavoprotein inhibitor, and apocynin
(2.5 × 10−3 mol/L; Calbiochem, Darmstadt, Germany), a
specific intracellular inhibitor of NADPH oxidase assem-
bly, were studied. To verify the specificity of the lucigenin
assay for •O2− production, the effect of superoxide dis-
mutase (SOD, 10000 U/mL, Sigma), an enzymatic scav-
enger of •O2− , was examined.
Although lucigenin concentration was low enough to
avoid auto-oxidation, the measurements were validated
against an independent measurement of •O2− produc-
tion using SOD-inhibitable ferricytochrome c reduction.
Mononuclear cells (4 × 105) were incubated in 500 lL of
buffer containing ferricytochrome c (80 lmol/L, Sigma)
at 37◦C for 60 minutes in the presence or absence of
SOD (10,000 U/mL, Sigma), and finally the absorbance
was measured at 550 nm. The PMA-stimulated pro-
duction measured by lucigenin-enhanced chemilumines-
cence was closely related with measurements determined
in parallel by ferricytochrome c reduction.
Oxidized LDL (oxLDL) concentrations in plasma
were measured by a sandwich enzyme-linked im-
munosorbent assay procedure using the murine mono-
clonal antibody, mAb-4E6, as the capture antibody bound
to microtitration wells, and a peroxidase-conjugated an-
tibody recognizing oxLDL bound to the solid phase
(oxLDL; Mercodia AB, Uppsala, Sweden).
Data are reported as means ± standard error. Sta-
tistical differences between mean values were tested by
the Student t test for unpaired data once normality was
demonstrated (Shapiro-Wilk test); otherwise, a Mann-
Whitney U test was used. Categorical variables were an-
alyzed with the v 2 Fisher’s exact test when necessary.
Correlation between continuously distributed variables
was analyzed by calculation of linear regression and cor-
relation coefficients. The significant level for all tests was
taken as P < 0.05.
RESULTS
Arterial hypertension and dyslipidemia were present
in 82% and 38% of patients with stage 1 to 2 CKD, re-
spectively. Obesity and diabetes mellitus were diagnosed
in 36% and 32% of patients with stage 1 to 2 CKD, respec-
tively. None of these conditions was present in patients
from the control group. Smoking was identified in 32%
of patients in each group. Thirteen patients with stage 1
to 2 CKD were under treatment with antihypertensive
and/or hypolipidemic and/or antidiabetic drugs when in-
cluded in the study. The remaining nine patients were free
of these medications.
The clinical characteristics of the studied patients are
summarized in Table 1. Insulin levels were higher (P =
0.001) in patients with stage 1 to 2 CKD than in controls.
In addition, patients with stage 1 to 2 CKD exhibited
increased carotid IMT compared with controls (0.74 ±
0.03 mm vs. 0.62 ± 0.03 mm, P < 0.005) (Fig. 1).
The PMA-stimulated •O2− production was inhibited
by diphenylene iodonium and apocynin. SOD and the
protein kinase C (PKC) inhibitor bisindolinmalenide I
(10 lmol/L) also abolished the cellular-induced increase
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Table 1. Clinical and biochemical parameters assessed in control
subjects and patients with stage 1 to 2 chronic kidney disease
Controls Patients P
Age years 48 ± 3 57 ± 2 0.013
Gender m/f 14/7 19/3 0.151
BMI kg/m2 25.5 ± 0.6 29.5 ± 0.9 0.001
SBP mm Hg 110 ± 2 141 ± 4 0.001
DBP mm Hg 72 ± 2 89 ± 3 0.001
Glucose mg/dL 91 ± 2 99 ± 2 0.014
Total cholesterol mg/dL 220 ± 12 230 ± 11 0.538
HDL-cholesterol mg/dL 52 ± 2 45 ± 10 0.019
LDL-cholesterol mg/dL 151 ± 11 154 ± 9 0.774
Triglycerides mg/dL 83 ± 4 130 ± 10 0.001
Insulin lU/mL 7.0 ± 0.4 15.8 ± 1.6 0.001
Glomerular filtration 90 ± 4 91 ± 4 0.875
rate mL/min/1.73 m2
Urine albumin: urine 3.6 ± 0.4 33.8 ± 2.4 0.001
creatinine mg/g
Abbreviations are: BMI, body mass index; SBP, systolic blood pres-
sure; DBP, diastolic blood pressure; HDL, high-density lipoproteins; LDL,
low-density lipoproteins. Values are mean ± standard error or number of subjects.
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Fig. 1. Carotid IMT in healthy controls (open bar) and patients with
stage 1 to 2 chronic kidney disease (closed bar). Data are presented as
mean + standard error.
in chemiluminescence under PMA-stimulated condi-
tions. No differences in basal levels of chemilumines-
cence derived from unstimulated cells were observed.
Thus, these results suggest that the enzymatic complex
of NADPH oxidase may be the enzymatic source of
•O2− from mononuclear cells under the conditions of
the present study.
The values of basal and PMA-stimulated •O2− produc-
tion in mononuclear cells from controls and patients with
stage 1 to 2 CKD are shown in Figure 2. Although the lev-
els of •O2− production from nonstimulated mononuclear
cells were higher in patients with stage 1 to 2 CKD than
in controls, the difference did not reach statistical signifi-
cance. The addition of PMA stimulated •O2− production
both in controls (1.2 ± 0.2 RLU/s vs. 5.7 ± 0.9 RLU/s,
P < 0.001
P < 0.001
P < 0.02
N.S.
Basal PMA-stimulated0
2
4
6
8
10
12
14
N
AD
PH
 o
xi
da
se
-d
ep
oe
nd
en
t
•
O
2-
 
pr
od
uc
tio
n 
(R
LU
/s)
Fig. 2. Baseline and PMA-stimulated NADPH oxidase–dependent su-
peroxide anion (·O2−) generation in healthy controls (open bars) and
patients with stage 1 to 2 chronic kidney disease (closed bars). Data
are presented as mean + standard error. RLU/s, relative light units per
second.
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Fig. 3. Direct correlation (y = 4.9 + 0.3x) between plasma insulin and
phorbol-myristate acetate-stimulated NADPH oxidase–dependent su-
peroxide anion (•O2−) generation in patients with stage 1 to 2 chronic
kidney disease.
P < 0.001) and patients with stage 1 to 2 CKD (2.1 ±
0.6 RLU/s vs. 10.5 ± 1.4 RLU/s, P < 0.001). The magni-
tude of this stimulation was higher (P < 0.05) in cells from
patients with stage 1 to 2 CKD than in cells from controls.
As a consequence, PMA-stimulated •O2− production
was higher (P < 0.02) in patients with stage 1 to 2 CKD
than in controls. Values of PMA-stimulated •O2− pro-
duction were above the upper normal limit (13.5 RLU/s)
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in 45% of patients with stage 1 to 2 CKD. There was
no difference in the values of basal and PMA-stimulated
NADPH oxidase–dependent •O2− production between
treated and untreated patients.
No differences in oxLDL were found between controls
and patients with stage 1 to 2 CKD (71.6 ± 6.6 U/L vs.
75.0 ± 5.5 U/L). The oxLDL values were not influenced
by treatment in patients with stage 1 to 2 CKD.
A direct correlation (r = 0.441, P < 0.05) was found
between insulin levels and NADPH oxidase activity in
patients with stage 1 to 2 CKD but not in controls (Fig. 3).
The frequency of patients with carotid IMT values were
above the upper normal limit in our laboratory of vascu-
lar radiology (0.69 mm) [12] was higher in patients with
elevated NADPH oxidase activity than in patients with
normal activity (70.5% vs. 40%), respectively, but the dif-
ference did not reach statistical significance.
DISCUSSION
The two major findings of this study are as follows:
(1) •O2− production is abnormally enhanced in PMA-
stimulated mononuclear cells from patients with stage 1
to 2 CKD, and (2) patients with stage 1 to 2 CKD exhibit
features of preclinical atherosclerosis (i.e., abnormally in-
creased carotid IMT).
The NADPH oxidase is a multicomponent enzyme
that has a membrane portion collectively known as cy-
tochrome b558, which is inactive until it is associated with
the cytosolic components (see [10] for review). Apoc-
ynin is a potent intracellular inhibitor of the assembly
of the NADPH oxidase on stimulation, because it im-
pedes the assembly of the p47phox and p67phox sub-
units within the membrane NADPH oxidase complex
[14]. This agent has no known inhibitory effects on the
other potential sources of reactive oxygen species [14].
Thus, our findings showing complete inhibition of PMA-
stimulated •O2− production observed in the presence
of apocynin strongly suggest that the enzymatic com-
plex of NADPH oxidase is the source of •O2−. In ac-
cordance with this, results presented here indicate that
NADPH oxidase activity is increased in patients with
stage 1 to 2 CKD. This observation expands on the previ-
ous data by Galli et al [15] who reported on abnormally
enhanced NADPH oxidase–mediated •O2− production
in neutrophils from hemodialysis patients. Collectively,
these findings suggest that phagocytic NADPH oxidase
may represent an early and maintained alteration in the
course of kidney disease.
The exaggerated response to PMA of cells from pa-
tients with stage 1 to 2 CKD might be the result of a
state of preactivation. In fact, it has been shown that
preactivated monocytes from patients with CKD exhibit
enhanced reactive oxygen species production and in-
creased release of cytokines on stimulation [16]. Under-
lying mechanisms for the increased •O2− production are
unclear, although some data suggest a critical role for
PKC-dependent p47phox and p67phox phosphorylation in
the regulation of NADPH oxidase activity in mononu-
clear cells [17]. In accordance with this possibility, we
found that increased PMA-stimulated •O2− production
was blocked by the PKC inhibitor, bisindolinmalenide I.
In addition, potential extracellular stimulating factors
of the NADPH oxidase enzymatic system deserve to be
considered. On the one hand, there is evidence that hy-
perinsulinemia may be involved in the generation of ox-
idative stress [18]. Insulin stimulates NADPH oxidase in
human cells, including adipocytes [19] and skin fibroblasts
[20]. Furthermore, insulin has been shown to enhance res-
piratory burst activity induced by PMA in human leuko-
cytes [21]. This is probably because insulin also activates
PKC [22]. The potential clinical relevance of these data is
remarked by our findings that insulin levels were abnor-
mally enhanced in patients with stage 1 to 2 CKD, and
that insulin was associated with NADPH oxidase activity
in these patients. On the other hand, in vitro experiments
show that advanced oxidation protein products (AOPP)
activate NADPH oxidase in human mononuclear cells
[23]. Interestingly, it has been reported that in vivo AOPP
levels are elevated early in the course of CKD (i.e., GFR
>80 mL/min/1.73 m2), increase with the progression of
the disease, and are closely related to monocyte activa-
tion state [24]. Clearly, further studies are necessary to
ascertain whether AOPP contribute to the overactivity
of NADPH oxidase seen in patients with stage 1 to 2
CKD.
Evidence substantiates that carotid IMT correlates
with the presence of coronary atherosclerosis and that
enhanced carotid IMT represents an independent risk
factor for coronary heart disease events, stroke, and tran-
sient cerebral ischemia [25]. Thus, our finding that carotid
IMT is abnormally increased in patients with stage 1 to
2 CKD reinforces the notion that the cardiovascular sys-
tem becomes affected by atherosclerosis in kidney dis-
ease well before the stage of kidney failure is reached [2],
and adds further support to the recent observation that
the smallest impairment in renal function associated with
a significant increase in cardiovascular risk is a GFR of
90 mL/min/1.73 m2 [11].
Upregulated expression of some subunits of the
NADPH oxidase and increased activity of the enzyme
have been reported in human atherosclerosis [26]. In
addition, enhanced phagocytic NADPH oxidase over-
activity has been shown recently to be associated with
increased carotid IMT in a large sample of 184 asymp-
tomatic patients [10]. Therefore, because NADPH ox-
idase overactivity and increased carotid IMT did tend
to be associated in patients with stage 1 to 2 CKD, it is
tempting to speculate that phagocytic NADPH oxidase–
derived •O2− can be involved in subclinical atheroscle-
rosis in these patients. •O2− may contribute to the
pathogenesis of atherosclerosis mediating the formation
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of oxLDL [27]. However, circulating levels of oxLDL
were not increased in patients with stage 1 to 2 CKD
compared with controls. Thus, alternative pathways must
be considered for the proatherogenic biologic actions of
•O2− in these patients [17]. Among these, the production
of reactive oxygen species induces stress responses that
alter phagocyte cell function, including adhesion, prolif-
eration, and motility. •O2− is also a very effective scav-
enger of nitric oxide and can thereby regulate endothe-
lial relaxation and, in the process, also generate highly
reactive peroxynitrite. In this regard, some available ev-
idence has led to the proposal that oxidative stress may
induce microinflammation and endothelial dysfunction
in patients with minor renal dysfunction [28].
In conclusion, this study demonstrates for the first time
that the production of •O2− by NADPH oxidase is in-
creased in PMA-stimulated mononuclear cells from pa-
tients with stage 1 to 2 CKD. Furthermore, our results
point to an association between hyperinsulinemia and ex-
aggerated phagocytic NADPH oxidase–dependent •O2−
production in these patients. Because this study was
performed in a small population of patients, further stud-
ies in larger samples are required to confirm whether
phagocytic NADPH oxidase–mediated oxidant stress
contributes to the development of atherosclerosis in the
initial stages of CKD.
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